Paliperidone (9-hydroxyrisperidone) is the active ingredient in Invega extended-release tablets. Paliperidone is also the major active metabolite of Risperidone. Steady-state concentrations are typically attained within 4 to 5 days of dosing. Following daily administration of 12 mg extended release formulation, paliperidone steady state plasma concentrations ranged from 30 to 40 ng/mL.
Reporting limit determined each analysis
8 - 12 days
Red top only, no SST
Collect specimen in a red top tube (NO SST). Spin and aliquot into a plastic, screw capped tube. Send to Specimen Processing refrigerated
Test sent to Mayo Clinic Labs; performed by NMS labs